[Induction of endogenous antitumor activities in the portal vein by using a subcutaneously-imbedded pediculated spleen in the rat; experimental study of adjuvant immunotherapy in liver metastases].
For the purpose of inducing the antitumor effect in the portal vein, the intrasplenic serial biological response modifier (BRM) administration was performed by using our original subcutaneously-imbedded pediculated spleen in the rats. In a view point of endogenous tumor necrosis factor (TNF) production, lipopolysaccharide, BCG and OK-432 were chosen and injected into the spleen frequently. The study of the portal blood serum revealed that intrasplenic (i.s.) BRM administration group gained higher TNF and interferon (IFN) activity than control group. On the other hand, the study of the mononuclear cells in the portal vein and splenocyte after i.s. BRM administration showed higher cytotoxic activity against YAC-1 cells than control group significantly. Compared with intravenous and intraperitoneal administration groups, i.s. group showed more effective antitumor effects in the portal vein significantly. The experimental liver metastases by intraportal transplantation of AH60C could be cured with i.s. BRM administration, which could increase % survival significantly. According to the result of this study, it is prospective that i.s. serial BRM administration could be new process for suppression of transportal hepatic metastases.
Fujii
M
M
Second Department of Surgery, Hirosaki University School of Medicine, Japan.
D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage; D003602:Cytotoxicity, Immunologic; D005260:Female; D007267:Injections / Q000379:methods; D007372:Interferons / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008114:Liver Neoplasms, Experimental / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D008297:Male; D010844:Picibanil / Q000008:administration & dosage; D011169:Portal Vein / Q000276:immunology*; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000637:transplantation*; D014182:Transplantation, Autologous / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D001500:BCG Vaccine; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D010844:Picibanil; D007372:Interferons